Asunto(s)

Mutación , Porfiria Cutánea Tardía/genética , Porfiria Hepatoeritropoyética/genética , Uroporfirinógeno Descarboxilasa/genética , Adulto , Eritrocitos/enzimología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Porfiria Cutánea Tardía/complicaciones , Porfiria Hepatoeritropoyética/complicaciones , Uroporfirinógeno Descarboxilasa/sangre

RESUMEN

BACKGROUND: Hemochromatosis gene (HFE) mutations and the hepatitis C virus (HCV) are known risk factors for porphyria cutanea tarda (PCT), but interactions with erythrocytic uroporphyrinogen decarboxylase (UROD) have seldom been addressed. OBJECTIVE: In order to examine the links between these factors, we conducted a multicentre prospective case-control study. METHODS: PCT patients with (n = 32) or without HCV (n = 28) were matched to HCV+ (n = 32) and HCV- controls (n = 28). HFE mutations (C282Y and H63D) were analyzed by PCR. RESULTS: PCT+/HCV+ patients were younger than PCT+/HCV- patients (46.9 vs. 58.2 years, p < 0.001). UROD values were not significantly different in HCV+ and HCV- patients. Both C282Y and H63D were more frequent in PCT+ patients than in controls, but there was no difference in HFE genotype according to HCV seropositivity. Mean UROD was lower in case of HFE mutations in both PCT patients and controls. CONCLUSION: In French patients, HCV infection is probably the major causal factor of PCT. It is not linked with HFE mutations, although they are significantly associated with PCT. A low erythrocytic UROD might be a predisposing factor. The UROD value was lower in patients with HFE mutations, suggesting a possible interaction between HFE genotype and UROD levels.

Asunto(s)

Hepatitis C/genética , Antígenos de Histocompatibilidad Clase I/genética , Proteínas de la Membrana/genética , Mutación , Porfiria Cutánea Tardía/genética , Uroporfirinógeno Descarboxilasa/sangre , Adulto , Anciano , Biomarcadores/sangre , Estudios de Casos y Controles , Femenino , Francia , Genotipo , Proteína de la Hemocromatosis , Hepatitis C/complicaciones , Hepatitis C/enzimología , Antígenos de Histocompatibilidad Clase I/sangre , Humanos , Masculino , Proteínas de la Membrana/sangre , Persona de Mediana Edad , Porfiria Cutánea Tardía/complicaciones , Porfiria Cutánea Tardía/enzimología , Estudios Prospectivos , Factores de Riesgo

RESUMEN

In patients with porphyria cutanea tarda (PCT), hepatic iron accumulation associated to hereditary hemochromatosis (HH) could play a role in the etiology and in the clinical expression of the disease. The H63D and C282Y mutations of the HFE gene frequency were studied in a PCT group of patients and compared with the frequency observed in a group of volunteer blood donors. PCT patients were cataloged as hereditary or acquired PCT carriers, whether or not they presented uroporphyrinogen decarboxilase gene mutations. Fifty percent of PCT patients were carriers of the disease's genetic type. Such percentage is significantly higher than what other authors have previously informed. H63D and C282Y mutations were present in 23% and 2.4% of the volunteer blood donors, respectively. Similar frequencies were informed by others authors in Chilean white ethnic populations, and also in Spaniard and Argentinean populations, but significantly higher than that observed in Chile's Araucanean aboriginal population. Probably the frequency of H63D and C283Y mutations are related to the Spaniard ascendancy dominance of Chile's white ethnic population. The frequency of HFE gene mutations in PCT patients was not different than what was observed in volunteer blood donors. Similarly, there was no statistical difference in the frequency of these mutations among patients with acquired or genetic PCT disease. With the obtained results, it is not possible postulate an association between PCT and the hereditary hemochromatosis of HFE gene mutations carrier conditions.

Asunto(s)

Donantes de Sangre , Hemocromatosis/genética , Mutación , Porfiria Cutánea Tardía/genética , Chile/etnología , Femenino , Frecuencia de los Genes , Tamización de Portadores Genéticos , Genotipo , Hemocromatosis/sangre , Proteína de la Hemocromatosis , Antígenos de Histocompatibilidad Clase I/genética , Humanos , Sobrecarga de Hierro , Masculino , Proteínas de la Membrana/genética , Porfiria Cutánea Tardía/sangre , Uroporfirinógeno Descarboxilasa/sangre , Uroporfirinógeno Descarboxilasa/genética

RESUMEN

Haemochromatosis is a hereditary iron-overload syndrome caused by increased intestinal iron absorption and characterised by accumulation of potentially toxic iron in the tissues. Sometimes this disease presents as a cutanea porphyria. We describe a patient with joint complaints and blistering skin lesions on sun-exposed skin. After identifying the porphyria cutanea tarda by urine analysis we found that the serum activity of uroporphyrinogen decarboxylase (UROD) was normal, meaning a partial inactivation of UROD in liver tissue due to external factors. Further investigation showed the homozygous Cys282Tyr missense mutation and high levels of serum ferritin. It is important to recognise the symptoms of iron overloading at an early stage because hereditary haemochromatosis needs to be treated immediately. We therefore advocate routine sampling of ferritin levels in patients with unexplained joint complaints.

Asunto(s)

Hemocromatosis/complicaciones , Porfiria Cutánea Tardía/etiología , ADN/genética , Diagnóstico Diferencial , Ferritinas/sangre , Hemocromatosis/sangre , Hemocromatosis/genética , Proteína de la Hemocromatosis , Antígenos de Histocompatibilidad Clase I/genética , Humanos , Masculino , Proteínas de la Membrana/genética , Persona de Mediana Edad , Mutación Missense , Porfiria Cutánea Tardía/sangre , Porfiria Cutánea Tardía/diagnóstico , Uroporfirinógeno Descarboxilasa/sangre

RESUMEN

La acumulación de hierro hepático asociada a mutaciones en el gen HFE de la hemocromatosis hereditaria (HH) en los pacientes con porfiria cutánea tarda (PCT) podría tener un papel en la etiología y en la expresión clínica de esta enfermedad. Se estudió la frecuencia de las mutaciones H63D y C282Y en un grupo de pacientes con PCT y se la comparó con la observada en un grupo de donantes voluntarios desangre. Los pacientes con PCT fueron catalogados como portadores de la forma hereditaria o adquirida de laenfermedad, según presentaran o no mutaciones en el gen uroporfirinógeno decarboxilasa (UROD). El 50% delos pacientes con PCT eran portadores de la forma genética de la enfermedad, porcentaje significativamentemayor que lo informado en otras series. El 23% de los donantes voluntarios de sangre eran portadores de lamutación H63D y 2.4% lo era de la mutación C282Y. Frecuencias similares a lo encontrado por otros autoresen población chilena de etnia blanca, en población argentina y española, pero significativamente más alta quelo encontrado en estudios en población aborigen araucana. Esto tiene, probablemente, relación con el predominio de ascendencia española en la población blanca chilena. La frecuencia de mutación en el gen HFE en pacientes con PCT no fue significativamente diferente que la observada en donantes voluntarios de sangre. Tampoco hubo diferencias significativas en la frecuencia de estas mutaciones entre los casos con PCT adquirida respecto de aquellos en que ésta era de origen genético. Los resultados obtenidos no permiten afirmar que exista asociación entre la PCT y la condición de portador de mutaciones del gen HFE de la hemocromatosis hereditaria

---

In patients with porphyria cutanea tarda (PCT), hepatic iron accumulation associated to hereditary hemochromatosis (HH) could play a role in the etiology and in the clinical expression of the disease. The H63D and C282Y mutations of the HFE gene frequency were studied in a PCT group of patients and compared with the frequency observed in a group of volunteer blood donors. PCT patients were cataloged as hereditary or acquired PCT carriers, whether or not they presented uroporphyrinogen decarboxilase gene mutations. Fifty percent of PCT patients were carriers of the disease’s genetic type. Such percentage is significantlyhigher than what other authors have previously informed. H63D and C282Y mutations were present in23% and 2.4% of the volunteer blood donors, respectively. Similar frequencies were informed by others authors in Chilean white ethnic populations, and also in Spaniard and Argentinean populations, but significantly higherthan that observed in Chile’s Araucanean aboriginal population. Probably the frequency of H63D and C283Y mutations are related to the Spaniard ascendancy dominance of Chile’s white ethnic population. The frequency of HFE gene mutations in PCT patients was not different than what was observed in volunteer blood donors.Similarly, there was no statistical difference in the frequency of these mutations among patients with acquired or genetic PCT disease. With the obtained results, it is not possible postulate an association between PCT and the hereditary hemochromatosis of HFE gene mutations carrier conditions

Asunto(s)

Humanos , Masculino , Femenino , Donantes de Sangre , Hemocromatosis/genética , Antígenos de Histocompatibilidad Clase I/genética , Mutación , Proteínas de la Membrana/genética , Porfiria Cutánea Tardía/genética , Chile/etnología , Frecuencia de los Genes , Genotipo , Tamización de Portadores Genéticos , Hemocromatosis/sangre , Sobrecarga de Hierro , Porfiria Cutánea Tardía/sangre , Uroporfirinógeno Descarboxilasa/sangre , Uroporfirinógeno Descarboxilasa/genética

RESUMEN

La acumulación de hierro hepático asociada a mutaciones en el gen HFE de la hemocromatosis hereditaria (HH) en los pacientes con porfiria cutánea tarda (PCT) podría tener un papel en la etiología y en la expresión clínica de esta enfermedad. Se estudió la frecuencia de las mutaciones H63D y C282Y en un grupo de pacientes con PCT y se la comparó con la observada en un grupo de donantes voluntarios desangre. Los pacientes con PCT fueron catalogados como portadores de la forma hereditaria o adquirida de laenfermedad, según presentaran o no mutaciones en el gen uroporfirinógeno decarboxilasa (UROD). El 50% delos pacientes con PCT eran portadores de la forma genética de la enfermedad, porcentaje significativamentemayor que lo informado en otras series. El 23% de los donantes voluntarios de sangre eran portadores de lamutación H63D y 2.4% lo era de la mutación C282Y. Frecuencias similares a lo encontrado por otros autoresen población chilena de etnia blanca, en población argentina y española, pero significativamente más alta quelo encontrado en estudios en población aborigen araucana. Esto tiene, probablemente, relación con el predominio de ascendencia española en la población blanca chilena. La frecuencia de mutación en el gen HFE en pacientes con PCT no fue significativamente diferente que la observada en donantes voluntarios de sangre. Tampoco hubo diferencias significativas en la frecuencia de estas mutaciones entre los casos con PCT adquirida respecto de aquellos en que ésta era de origen genético. Los resultados obtenidos no permiten afirmar que exista asociación entre la PCT y la condición de portador de mutaciones del gen HFE de la hemocromatosis hereditaria (AU)

---

In patients with porphyria cutanea tarda (PCT), hepatic iron accumulation associated to hereditary hemochromatosis (HH) could play a role in the etiology and in the clinical expression of the disease. The H63D and C282Y mutations of the HFE gene frequency were studied in a PCT group of patients and compared with the frequency observed in a group of volunteer blood donors. PCT patients were cataloged as hereditary or acquired PCT carriers, whether or not they presented uroporphyrinogen decarboxilase gene mutations. Fifty percent of PCT patients were carriers of the diseaseãs genetic type. Such percentage is significantlyhigher than what other authors have previously informed. H63D and C282Y mutations were present in23% and 2.4% of the volunteer blood donors, respectively. Similar frequencies were informed by others authors in Chilean white ethnic populations, and also in Spaniard and Argentinean populations, but significantly higherthan that observed in Chileãs Araucanean aboriginal population. Probably the frequency of H63D and C283Y mutations are related to the Spaniard ascendancy dominance of Chileãs white ethnic population. The frequency of HFE gene mutations in PCT patients was not different than what was observed in volunteer blood donors.Similarly, there was no statistical difference in the frequency of these mutations among patients with acquired or genetic PCT disease. With the obtained results, it is not possible postulate an association between PCT and the hereditary hemochromatosis of HFE gene mutations carrier conditions (AU)

Asunto(s)

Humanos , Masculino , Femenino , Donantes de Sangre , Mutación , Hemocromatosis/genética , Proteínas de la Membrana/genética , Antígenos de Histocompatibilidad Clase I/genética , Porfiria Cutánea Tardía/genética , Chile/etnología , Frecuencia de los Genes , Genotipo , Hemocromatosis/sangre , Tamización de Portadores Genéticos , Sobrecarga de Hierro , Porfiria Cutánea Tardía/sangre , Uroporfirinógeno Descarboxilasa/sangre , Uroporfirinógeno Descarboxilasa/genética

RESUMEN

La acumulación de hierro hepático asociada a mutaciones en el gen HFE de la hemocromatosis hereditaria (HH) en los pacientes con porfiria cutánea tarda (PCT) podría tener un papel en la etiología y en la expresión clínica de esta enfermedad. Se estudió la frecuencia de las mutaciones H63D y C282Y en un grupo de pacientes con PCT y se la comparó con la observada en un grupo de donantes voluntarios desangre. Los pacientes con PCT fueron catalogados como portadores de la forma hereditaria o adquirida de laenfermedad, según presentaran o no mutaciones en el gen uroporfirinógeno decarboxilasa (UROD). El 50% delos pacientes con PCT eran portadores de la forma genética de la enfermedad, porcentaje significativamentemayor que lo informado en otras series. El 23% de los donantes voluntarios de sangre eran portadores de lamutación H63D y 2.4% lo era de la mutación C282Y. Frecuencias similares a lo encontrado por otros autoresen población chilena de etnia blanca, en población argentina y española, pero significativamente más alta quelo encontrado en estudios en población aborigen araucana. Esto tiene, probablemente, relación con el predominio de ascendencia española en la población blanca chilena. La frecuencia de mutación en el gen HFE en pacientes con PCT no fue significativamente diferente que la observada en donantes voluntarios de sangre. Tampoco hubo diferencias significativas en la frecuencia de estas mutaciones entre los casos con PCT adquirida respecto de aquellos en que ésta era de origen genético. Los resultados obtenidos no permiten afirmar que exista asociación entre la PCT y la condición de portador de mutaciones del gen HFE de la hemocromatosis hereditaria (AU)

---

In patients with porphyria cutanea tarda (PCT), hepatic iron accumulation associated to hereditary hemochromatosis (HH) could play a role in the etiology and in the clinical expression of the disease. The H63D and C282Y mutations of the HFE gene frequency were studied in a PCT group of patients and compared with the frequency observed in a group of volunteer blood donors. PCT patients were cataloged as hereditary or acquired PCT carriers, whether or not they presented uroporphyrinogen decarboxilase gene mutations. Fifty percent of PCT patients were carriers of the diseaseãs genetic type. Such percentage is significantlyhigher than what other authors have previously informed. H63D and C282Y mutations were present in23% and 2.4% of the volunteer blood donors, respectively. Similar frequencies were informed by others authors in Chilean white ethnic populations, and also in Spaniard and Argentinean populations, but significantly higherthan that observed in Chileãs Araucanean aboriginal population. Probably the frequency of H63D and C283Y mutations are related to the Spaniard ascendancy dominance of Chileãs white ethnic population. The frequency of HFE gene mutations in PCT patients was not different than what was observed in volunteer blood donors.Similarly, there was no statistical difference in the frequency of these mutations among patients with acquired or genetic PCT disease. With the obtained results, it is not possible postulate an association between PCT and the hereditary hemochromatosis of HFE gene mutations carrier conditions (AU)

Asunto(s)

Humanos , Masculino , Femenino , Donantes de Sangre , Mutación , Hemocromatosis/genética , Proteínas de la Membrana/genética , Antígenos de Histocompatibilidad Clase I/genética , Porfiria Cutánea Tardía/genética , Chile/etnología , Frecuencia de los Genes , Genotipo , Hemocromatosis/sangre , Tamización de Portadores Genéticos , Sobrecarga de Hierro , Porfiria Cutánea Tardía/sangre , Uroporfirinógeno Descarboxilasa/sangre , Uroporfirinógeno Descarboxilasa/genética

RESUMEN

Uroporphyrinogen decarboxylase (UROD) and coproporphyrinogen oxidase (copro'gen oxidase) are two of the least well understood enzymes in the heme biosynthetic pathway. In the fifth step of the pathway, UROD converts uroporphyrinogen III to coproporphyrinogen III by the decarboxylation of the four acetic acid side chains. Copro'gen oxidase then converts coproporphyrinogen III to protoporphyrinogen IX via two sequential oxidative decarboxylations. Studies of these two enzymes are important to increase our understanding of their mechanisms. Assay comparisons of UROD and copro'gen oxidase from chicken blood hemolysates (CBH), using a newly developed micro-assay, showed that the specific activity of both enzymes is increased in the micro-assay relative to the large-scale assay. The micro-assay has distinct advantages in terms of cost, labor intensity, amount of enzyme required, and sensitivity.

Asunto(s)

Cromatografía Líquida de Alta Presión/métodos , Coproporfirinógeno Oxidasa/análisis , Coproporfirinógeno Oxidasa/química , Uroporfirinógeno Descarboxilasa/análisis , Uroporfirinógeno Descarboxilasa/química , Animales , Pollos , Coproporfirinógeno Oxidasa/sangre , Activación Enzimática , Eritrocitos/enzimología , Uroporfirinógeno Descarboxilasa/sangre

RESUMEN

Porphyria cutanea tarda (PCT) is a human metabolic disorder due to the acquired or genetic impairment of uroporphyrinogen decarboxylase (URO-D) activity, the fifth enzyme of the heme biosynthetic pathway. A classification of inherited and non-inherited forms is based on the enzyme activity levels in red blood cells (RBC). Clinical manifestations of PCT are often precipitated by triggering factors such as alcohol, drug abuse, estrogens, virus infections, hepatotoxic chemicals and hepatic siderosis. We measured URO-D activity in RBC from a large sample of Italian PCT patients in order to define the enzyme activity distribution and to attempt a correlation among activity, risk factors and clinical outcome. Three classes of patients with low, normal and over-normal URO-D activity were defined according to control values. Low URO-D levels were present in 25.8% of patients, suggesting the familial form of PCT (type II). In this group, the outcome of PCT seems to be less influenced by risk factors. Patients with over-normal URO-D activity in RBC deserve further investigation.

Asunto(s)

Eritrocitos/enzimología , Porfiria Cutánea Tardía/enzimología , Uroporfirinógeno Descarboxilasa/sangre , Adulto , Anciano , Anciano de 80 o más Años , Consumo de Bebidas Alcohólicas/efectos adversos , Femenino , Proteína de la Hemocromatosis , Antígenos de Histocompatibilidad Clase I/genética , Humanos , Italia/epidemiología , Masculino , Proteínas de la Membrana/genética , Persona de Mediana Edad , Porfiria Cutánea Tardía/etiología , Porfirinas/orina , Pronóstico , Factores de Riesgo

RESUMEN

Erythrocyte uroporphyrinogen decarboxylase (UROD) activity was measured to classify 118 Spanish patients with porphyria cutanea tarda (PCT) into three subtypes: sporadic-, familial- and type III-PCT. Seventy-four patients (63%) had eythrocyte UROD activity within the normal range (74% to 126% of the mean activity of 43 healthy controls) and were classified as sporadic-PCT (47%) or as type III-PCT (16%) whenever a family history of PCT was documented. Forty-four patients (37%) had decreased UROD activity and were classified as familial-PCT. The frequency of both familial-PCT and type III-PCT was higher than reported in other countries. The clinical expression of PCT was associated with the coexistence of two or more risk factors in 80% of the sporadic-PCT patients and in 89% of the familial-PCT patients. Hepatitis C virus and alcohol abuse were risk factors frequently found in these patients, being unrelated to age of onset of skin lesions. A heavy alcohol intake was the main risk factor for type III-PCT. Estrogens appeared as a precipitating factor for women with familial-PCT. The H63D mutation in the hemochromatosis type 1 gene was more frequently found than the C282Y mutation. Both mutations appeared to play a role as precipitating factors in sporadic-PCT when associated with hepatitis C virus infection and alcohol abuse.

Asunto(s)

Porfiria Cutánea Tardía/diagnóstico , Porfiria Cutánea Tardía/genética , Adulto , Edad de Inicio , Consumo de Bebidas Alcohólicas , Alelos , Estrógenos/metabolismo , Salud de la Familia , Femenino , Predisposición Genética a la Enfermedad , Hemocromatosis/genética , Proteína de la Hemocromatosis , Hepatitis C/complicaciones , Antígenos de Histocompatibilidad Clase I/genética , Humanos , Masculino , Proteínas de la Membrana/genética , Persona de Mediana Edad , Mutación , Porfiria Cutánea Tardía/etiología , Porfiria Cutánea Tardía/virología , Factores de Riesgo , España , Uroporfirinógeno Descarboxilasa/sangre

RESUMEN

Background: Porphyria cutanea tarda (PCT) is due to a partial defect of hepatic uroporphyrinogen decarboxylase (URO-D). In the hereditary form, both hepatic and erythrocytic enzymes are altered, whereas in the acquired form, only the hepatic enzyme fails. There is a high prevalence of hepatitis C virus infection in patients with PCT, specially in those without family history of the disease. Aim: To study erythrocytic URO-D activity in order to find out wether hepatitis C virus infection is associated to the acquired form of PCT or unveils an inactive hereditary form. Patients and methods: URO-D activity was measured in red blood cells of normal controls, hepatitis C virus carriers without symptoms of PCT and patients with PCT, with and without family history of the disease, with and without anti hepatitis C virus antibodies. Results: URO-D activity was similar in normal controls, patients with chronic liver disease associated to hepatitis C virus, and in patients with PCT without family history of the disease with and without hepatitis C virus antibodies. URO-D activity was lower in patients with PCT and family history of the disease, with and without hepatitis C virus antibodies. Conclusions: PCT in patients with hepatitis C virus infection is due to an acquired alteration of hepatic URO-D. Hepatitis C virus does not modify erythrocytic URO-D

Asunto(s)

Humanos , Hepacivirus/patogenicidad , Hepatitis C Crónica/complicaciones , Porfiria Cutánea Tardía/etiología , Pruebas de Función Hepática/métodos , Uroporfirinógeno Descarboxilasa/orina , Uroporfirinógeno Descarboxilasa/sangre

RESUMEN

A marked discrepancy between mild and late clinical features and a nearly complete absence of erythrocyte uroporphyrinogen decarboxylase activity (Ery-UROD activity) was observed in a case of inherited porphyria cutanea tarda. The entity and time of appearance of clinical features, the onset of clinical symptoms after exposure to contributing factors, the effectiveness of phlebotomies and heterozygosity of the mother alone for uroporphyrinogen decarboxylase (UROD) deficiency were typical for familial porphyria cutanea tarda (F-PCT), whereas the extremely low UROD activity was peculiar to hepatoerythropoietic porphyria (HEP). These observations indicate that: 1) Ery-UROD activity may not always be useful to discriminate between F-PCT and HEP; 2) Ery-UROD activity does not always correlate with clinical symptoms; 3) in inherited UROD deficiency, the genetic defect may be heterogeneous. Finally, the observed discrepancy may provide additional evidence for the existence of tissue-specific isozymes.

Asunto(s)

Eritrocitos/enzimología , Porfiria Cutánea Tardía/diagnóstico , Porfiria Cutánea Tardía/genética , Uroporfirinógeno Descarboxilasa/sangre , Adulto , Biomarcadores/sangre , Consanguinidad , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Linaje , Porfiria Cutánea Tardía/terapia , Porfirinas/sangre , Porfirinas/orina

RESUMEN

Hexachlorobenzene (HCB)-induced porphyria occurs in female, but not male, rats after a delay of 35 days following HCB treatment. Uroporphyrinogen decarboxylase (UROD) inhibition has been proposed as a primary causative event. To determine whether there also exists a delay phase and a sexual dimorphism for UROD inhibition, groups of male and female rats were given HCB (100 mg/kg/day) from Days 1 to 5. Hepatic uroporphyrin III was markedly increased only after Day 33. Liver cytosol UROD activity in HCB-treated female rats with porphyria at Days 33, 40, 47, 54, and 100 was decreased by over 70% compared to concurrent control, whereas treated male rats as well as nonporphyric female rats had UROD activity comparable to control levels at Days 6, 12, 19, 26, 33, 40, 47, and 54. Level of immunoreactive UROD in cytosol of porphyric rats was not modified by HCB. No gender-related differences in liver cytosol radiolabel level ([14C]HCB given as the fifth dose) were found at Days 6 and 30. Chromatography of liver cytosol showed nonspecific binding of radiolabel to proteins for males, porphyric and nonporphyric females, and loss of UROD activity did not correlate with the amount of radiolabel in the UROD-containing fractions. Thus, the gender-specific decrease in UROD activity observed when porphyria develops in female rats (delay of about 4 weeks), as well as the persistence of low activity and porphyria for months, suggests that UROD inhibition was causally related to porphyria.

Asunto(s)

Fungicidas Industriales/toxicidad , Hexaclorobenceno/toxicidad , Hígado/efectos de los fármacos , Porfirias Hepáticas/enzimología , Uroporfirinógeno Descarboxilasa/antagonistas & inhibidores , Análisis de Varianza , Animales , Radioisótopos de Carbono , Cromatografía en Gel , Cromatografía Líquida de Alta Presión , Citosol/efectos de los fármacos , Citosol/enzimología , Diálisis , Relación Dosis-Respuesta a Droga , Electroforesis en Gel de Poliacrilamida , Femenino , Fungicidas Industriales/administración & dosificación , Hexaclorobenceno/administración & dosificación , Marcaje Isotópico , Hígado/enzimología , Hígado/metabolismo , Masculino , Porfirias Hepáticas/inducido químicamente , Ratas , Ratas Sprague-Dawley , Caracteres Sexuales , Uroporfirinógeno Descarboxilasa/sangre , Uroporfirinas/metabolismo , Uroporfirinas/orina

Asunto(s)

Eritrocitos/enzimología , Uroporfirinógeno Descarboxilasa/sangre , Uroporfirinógeno Descarboxilasa/aislamiento & purificación , Coproporfirinógenos/metabolismo , Inhibidores Enzimáticos/farmacología , Hemo/biosíntesis , Humanos , Cinética , Metales/farmacología , Peso Molecular , Uroporfirinógeno Descarboxilasa/antagonistas & inhibidores , Uroporfirinógeno Descarboxilasa/química , Uroporfirinógenos/metabolismo , Uroporfirinas/farmacología

Asunto(s)

Enfermedades Hematológicas/enzimología , Hidroximetilbilano Sintasa/sangre , Uroporfirinógeno Descarboxilasa/sangre , Adulto , Eritrocitos Anormales , Femenino , Enfermedades Hematológicas/sangre , Humanos

Asunto(s)

Coproporfirinas/análisis , Heces/química , Porfiria Cutánea Tardía/metabolismo , Eritrocitos/enzimología , Humanos , Porfiria Cutánea Tardía/genética , Uroporfirinógeno Descarboxilasa/sangre , Uroporfirinógeno Descarboxilasa/metabolismo

RESUMEN

There are 4 different porphyrin-synthesizing enzymes, i.e. delta-aminolevulinic acid dehydratase, porphobilinogen deaminase, uroporphyrinogen III synthase and uroporphyrinogen decarboxylase, in red blood cells. Determination of activities of these enzymes is of great help in clarifying the hemopoietic mechanism operating in bone marrow erythroblasts, as well as, in establishing the diagnosis of or early detection of acute intermittent porphyria, congenital erythropoietic porphyria, delta-aminolevulinic acid dehydratase deficiency porphyria, porphyria cutanea tarda and lead poisoning. This paper presents a summary of the techniques for the measuring, diagnostic criteria for and clinical implications of activities of these 4 enzymes in red blood cells.

Asunto(s)

Eritrocitos/enzimología , Porfirias/diagnóstico , Pruebas Enzimáticas Clínicas , Humanos , Hidroximetilbilano Sintasa/sangre , Porfobilinógeno Sintasa/sangre , Uroporfirinógeno Descarboxilasa/sangre , Uroporfirinógeno III Sintetasa/sangre

RESUMEN

Raised plasma uroporphyrin levels were found in all the 14 patients with end-stage renal disease studied, 7 of whom were on continuous ambulatory peritoneal dialysis (CAPD) and 7 on hemodialysis (HD). The elevation observed in the HD group was higher than that noted in the CAPD group; 18-fold in the former and 13-fold in the latter. The difference in uroporphyrin plasma levels between the two dialysis populations might be explained, at least partially, by the reduced activity of uroporphyrinogen decarboxylase (UROD), the enzyme which converts uroporphyrinogen to coproporphyrinogen. A decrease of 48% was noted in the HD group, whereas no change was observed in the CAPD group. A significant negative correlation (r = -0.37, p < 0.01) was found between the concentration of uroporphyrin in plasma and the activity of UROD. In view of the data shown, it is suggested that erythrocyte UROD activity should be interpreted with caution in HD patients suspected of having porphyria cutanea tarda.

Asunto(s)

Fallo Renal Crónico/sangre , Diálisis Renal , Uroporfirinógeno Descarboxilasa/sangre , Cromatografía Líquida de Alta Presión , Coproporfirinas/sangre , Humanos , Fallo Renal Crónico/enzimología , Diálisis Peritoneal Ambulatoria Continua , Uroporfirinas/sangre

RESUMEN

We describe multiple alternative transcripts of uroporphyrinogen decarboxylase mRNA in normal individuals and patients with familial porphyria cutanea tarda. mRNA was reverse-transcribed, subjected to the polymerase chain reaction, and analyzed for nucleotide sequence. Seven different transcripts were characterized, and a cryptic splice acceptor site was identified in intron 1. In all mRNAs the exons abutted at previously defined exon boundaries. Characterization of the splice junctions in the genomic DNA showed that splice donor and acceptor sequences complied with the consensus sequences for these sites except for the splice acceptor sequences of exons 3 and 10. THese deviations were present in two normal individuals and one patient with familial porphyria cutanea tarda and were thus unable to explain the multiple aberrant uroporphyrinogen decarboxylase transcripts. We conclude that apparent deletions observed in transcripts derived from the uroporphyrinogen decarboxylase gene in patients with familial porphyria cutanea tarda should be interpreted with caution.

Asunto(s)

Empalme Alternativo , Porfiria Cutánea Tardía/genética , Uroporfirinógeno Descarboxilasa/genética , Secuencia de Bases , Eritrocitos/enzimología , Exones , Humanos , Intrones , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa , Porfiria Cutánea Tardía/diagnóstico , ARN Mensajero/análisis , ARN Mensajero/química , Valores de Referencia , Uroporfirinógeno Descarboxilasa/sangre

RESUMEN

In a considerable proportion of the patients with chronic renal failure, skin changes resembling porphyria cutanea tarda (PCT) develop some months to years after the onset of maintenance hemodialysis. This can be either real PCT, or secondary PCT, or PCT-like bullous dermatosis. In a minor proportion, real PCT can be diagnosed. In such cases, elevated total porphyrin levels with a predominance of uro- (I > III) and heptacarboxyl porphyrins (III > I) can be measured in the plasma (also in the urine, if not anuric), and fecal (perhaps urinary as well) isocoproporphyrin can be detected. The activity of the hepatic uroporphyrinogen decarboxylase (UD) is decreased in every type of PCT; in PCT-II, also that of the erythrocyte UD. In a higher proportion, secondary PCT (pseudo-PCT) develops. In this group, porphyrins are accumulated in the plasma due to the unsatisfactory renal function. Uro and hepta are the dominant fractions here as well, but alteration in the ratio of the uro isomers or the presence of isocoproporphyrin can not be expected. The UD activity is probably normal in every tissue. In 1% to 18% of the cases, PCT-like bullous dermatoses develop, but porphyrins are at normal levels in all compartments. The phototoxic agent here is other than porphyrin (e.g. nalidixic acid, furosemide, tetracycline, etc., or unknown). The authors review the knowledge on chronic hemodialysis-related PCT or the PCT-like bullous dermatoses: development of the above-mentioned conditions, clinical and morphological and biochemical features, difficulties in diagnosis, or the possibilities in therapy.

Asunto(s)

Fallo Renal Crónico/terapia , Porfiria Cutánea Tardía/etiología , Diálisis Renal/efectos adversos , Enfermedades Cutáneas Vesiculoampollosas/etiología , Femenino , Humanos , Fallo Renal Crónico/metabolismo , Masculino , Uroporfirinógeno Descarboxilasa/sangre , Uroporfirinas/sangre